{"database": "lobbying", "table": "lobbying_activities", "rows": [[2511518, "b94f8f57-864e-4503-89f6-e8670e022562", "Q3", "BURRELL INTERNATIONAL GROUP LLC", 401103483, "HOMOLOGY MEDICINES", 2020, "third_quarter", "MED", "Drug pricing and gene therapy, generally;\nH.R. 4393 - Advancing Access to Precision Medicine;\nH.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act;\nH.R. 8045 - Genome Editing Threat Assessment Act;\nHR 2501 - Medical Nutrition Equity Act;", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2020-10-16T14:54:22.630000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2511518"], "units": {}, "query_ms": 0.317147932946682, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}